Program
culmerciclib
Also written as “TQB3616 capsules”, “TQB3616 capsule” and “TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen”.
In Sino Biopharmaceutical's pipeline, CDK2/4/6抑制剂
. Its studies are mostly in Breast Neoplasms · Liposarcoma, led by Sino Biopharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 115 open or running | phase 3since Apr 26, 2022 | Feb 20, 2019 | Dec 2026phase 3 · NCT05780567 |
- Named in Sino Biopharmaceutical’s own pipeline as
TQB3616
, phase 4, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 20, 2019First study: phase 1 study in Advanced Breast CancerFirst studyNCT03850873 · 40 enrolled · China
- Mar 11, 2021Phase 2 study in HR-positive, HER2-negative Advanced Breast CancerNCT04796623 · 122 enrolled · China
- Apr 1, 2022Phase 1 study in Breast NeoplasmsNCT05344729 · 16 enrolled · China
- Apr 26, 2022Phase 3 study in HR-positive, HER2-negative Breast NeoplasmsNCT05365178 · 432 enrolled · China
- May 11, 2022Phase 3 study in HR-positive,HER2-negative in Advanced Breast CancerNCT05375461 · 293 enrolled · China
- Aug 9, 2022Phase 2 study in LiposarcomaNCT05496569 · 26 enrolled · China
- Mar 10, 2023Phase 3 study in Breast NeoplasmsNCT05780567 · 1,946 enrolled · China
- Nov 21, 2023Phase 1 study in Breast NeoplasmsNCT06149611 · 8 planned · China
- Oct 28, 2024Phase 1 study in HealthyNCT06662773 · 40 planned · China
- Nov 20, 2024Phase 2 study in Breast NeoplasmsNCT06702618 · 33 enrolled · China
- Feb 22, 2025Phase 2 study in Breast NeoplasmsNCT06851442 · 8 enrolled · China
Ahead
- Dec 2026Primary completion: phase 3 study in Breast NeoplasmsNCT05780567
TargetBeta
“CDK2/4/6抑制剂”the company's pipeline, read by Claude · source
“An orally bioavailable, selective inhibitor of cyclin-dependent kinase (CDK) types 4 (CDK4) and 6 (CDK6), ”NCIt, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| vustanaciclib | regor-pharmaceuticals-inc | phase 2 | 3 |
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06851442Breast Neoplasms · China | 2 | Terminated | Nov 20, 2025 | 8 |
| NCT06702618Breast Neoplasms · China | 2 | Active, not recruiting | Jun 2026 | 33 |
| NCT06662773Healthy · China | 1 | Not yet recruiting | Mar 2025 | 40 |
| NCT06149611Breast Neoplasms · China | 1 | Not yet recruiting | Jun 2024 | 8 |
| NCT05780567Breast Neoplasms · China | 3 | Active, not recruiting | Dec 2026 | 1,946 |
| NCT05496569Liposarcoma · China | 2 | Terminated | Jun 15, 2024 | 26 |
| NCT05375461HR-positive,HER2-negative in Advanced Breast Cancer · China | 3 | Completed | Jan 16, 2024 | 293 |
| NCT05365178HR-positive, HER2-negative Breast Neoplasms · China | 3 | Active, not recruiting | Jul 2, 2025 | 432 |
| NCT05344729Breast Neoplasms · China | 1 | Completed | Aug 30, 2021 | 16 |
| NCT04796623HR-positive, HER2-negative Advanced Breast Cancer · China | 2 | Completed | May 24, 2024 | 122 |
| NCT03850873Advanced Breast Cancer · China | 1 | Completed | Sep 23, 2021 | 40 |
How it is read
Names in the registry
- “TQB3616 capsules”, 2 entries
- “TQB3616 capsule”, 2 entries
- “TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen”, 1 entry
- “TQB3616”, 1 entry
- “TQB3616 capsule+Fulvestrant Injection”, 1 entry
Codes read as this program: TQB3616.
Conditions, from the studies’ own filings
- Breast Neoplasms, 9 studies
- Liposarcoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.